Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 MillionGlobeNewsWire • 07/25/25
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged CompanyGlobeNewsWire • 07/23/25
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene BiopharmaceuticalsGlobeNewsWire • 07/15/25
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene BiopharmaceuticalsGlobeNewsWire • 07/11/25
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementGlobeNewsWire • 12/23/24
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateGlobeNewsWire • 05/13/24
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundZacks Investment Research • 02/14/24
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a TurnaroundZacks Investment Research • 01/24/24
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/09/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ikena Oncology Inc. (NASDAQ: IKNA)PRNewsWire • 10/02/23
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/23